Guardant Health is a precision oncology company that develops blood tests (liquid biopsies) to detect and monitor cancer from circulating tumor DNA. Co-founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, it is public (NASDAQ: GH). Khosla Ventures led its $30 million Series B in 2014.